Michael Celano's Insider Trades & SAST Disclosures
Michael Celano's most recent trade in Larimar Therapeutics Inc was a trade of 205,111 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Celano.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 205,111 | 205,111 | - | - | Stock Option (Right to Buy) | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 34,185 | 178,181 | - | 0 | Common Stock | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 187,500 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Larimar Therapeutics Inc | Celano Michael | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 31,250 | 143,996 | - | 0 | Common Stock | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.73 per share. | 17 May 2023 | 5,000 | 112,746 | - | 3.7 | 18,632 | Common Stock |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 76,000 | 107,746 | - | 0 | Common Stock | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.15 per share. | 16 Sep 2022 | 31,746 | 31,746 | - | 3.2 | 100,000 | Common Stock |
| Orasure Technologies Inc. | Michael Celano | Director | Purchase of securities on an exchange or from another person at price $ 4.49 per share. | 12 Aug 2022 | 12,000 | 111,823 (0%) | 0% | 4.5 | 53,916 | Common Stock |
| Orasure Technologies Inc. | Michael Celano | Director | Grant, award, or other acquisition of securities at price $ 5.25 per share. | 16 May 2022 | 24,762 | 99,823 (0%) | 0% | 5.3 | 130,001 | Common Stock |
| Orasure Technologies Inc. | Michael Celano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.25 per share. | 16 May 2022 | 3,399 | 75,061 (0%) | 0% | 5.3 | 17,845 | Common Stock |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Orasure Technologies Inc. | Michael Celano | Director | Grant, award, or other acquisition of securities at price $ 9.59 per share. | 17 May 2021 | 13,559 | 78,460 (0%) | 0% | 9.6 | 129,997 | Common Stock |
| Orasure Technologies Inc. | Michael Celano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 17 May 2021 | 2,041 | 64,901 (0%) | 0% | 9.5 | 19,392 | Common Stock |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2020 | 84,100 | 84,100 | - | - | Stock Option (right to buy) | |
| Larimar Therapeutics Inc | Michael Celano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 60,479 | 60,479 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges